Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 25:12:626924.
doi: 10.3389/fendo.2021.626924. eCollection 2021.

Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI)

Affiliations
Review

Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI)

Bunpei Ishizuka. Front Endocrinol (Lausanne). .

Abstract

Premature ovarian insufficiency (POI) occurs in at least 1% of all women and causes life-long health problems and psychological stress. Infertility caused by POI used to be considered absolute, with infertility treatment having little or no value. Generally, it has been thought that medicine can provide little service to these patients. The etiology of POI has been found to be genetic, chromosomal, and autoimmune. In addition, the increasing numbers of cancer survivors are candidates for iatrogenic POI, along with patients who have undergone ovarian surgery, especially laparoscopic surgery. Over 50 genes are known to be causally related to POI, and the disease course of some cases has been clarified, but in most cases, the genetic background remains unexplained, suggesting that more genes associated with the etiology of POI need to be discovered. Thus, in most cases, the genetic background of POI has not been clarified. Monosomy X is well known to manifest as Turner's syndrome and is associated with primary amenorrhea, but recent studies have shown that some women with numerical abnormalities of the X chromosome can have spontaneous menstruation up to their twenties and thirties, and some even conceive. Hormone replacement therapy (HRT) is recommended for women with POI from many perspectives. It alleviates vasomotor and genitourinary symptoms and prevents bone loss and cardiovascular disease. POI has been reported to reduce quality of life and life expectancy, and HRT may help improve both. Most of the problems that may occur with HRT in postmenopausal women do not apply to women with POI; thus, in POI, HRT should be considered physiological replacement of estrogen (+progesterone). This review describes some new approaches to infertility treatment in POI patients that may lead to new treatments for POI, along with the development of more sensitive markers of secondary/preantral follicles and genetic diagnosis.

Keywords: autoimmunity; cardiovascular disease; chromosomal abnormality; genetics; hormone replacement therapy (HRT); ovulation induction; premature ovarian insufficiency (POI); vasomotor symptoms.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Period of onset of ovarian insufficiency post-ovarian surgery for each patient by age. A strong correlation is observed between age at the time of surgery and the period of onset of ovarian insufficiency (correlation coefficient: −0.63, Spearman’s rank correlation coefficient) (45).
Figure 2
Figure 2
Timing of onset of hot flushes (year from the onset of amenorrhea), 66% (132/200) of the POI patients reported the experience of hot flushes (11).

Similar articles

Cited by

References

    1. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol (2006) 7:821–8. 10.1016/S1470-2045(06)70869-5 - DOI - PubMed
    1. ESHRE POI Guideline Development Group . Management of women with premature ovarian insufficiency. Guideline Eur Soc Hum Reprod Embryol (2015) p. 30.
    1. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol (1986) 67:604–6. 10.1097/00006254-198703000-00020 - DOI - PubMed
    1. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod (2003) 18:199–206. 10.1093/humrep/deg005 - DOI - PubMed
    1. Lagergeren K, Hammar M, Nedstrand E, Bladh M, Sydsjö G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health (2018) 18:175. 10.1186/s12905-018-0665-2 - DOI - PMC - PubMed

MeSH terms